Schonfeld Strategic Advisors’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-7,600	Closed	-$384K	–	2026
2020 Q3	$384K	Buy	+7,600	New	+$342K	0.01%	999
2020 Q1	–	Sell	-21,800	Closed	-$1.25M	–	1679
2019 Q4	$1.25M	Sell	21,800 -76,800	-78%	-$3.8M	0.03%	451
2019 Q3	$3.55M	Buy	98,600 +30,699	+45%	+$1.2M	0.1%	210
2019 Q2	$2.11M	Sell	67,901 -117,399	-63%	-$3.18M	0.07%	281
2019 Q1	$4.34M	Buy	+185,300	New	+$2.97M	0.15%	182
2018 Q4	–	Sell	-10,000	Closed	-$100K	–	1301
2018 Q3	$100K	Buy	+10,000	New	+$164K	﹤0.01%	770

Other funds holding EIDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Schonfeld Strategic Advisors's EIDX Position: Q4 2020 in Review

Schonfeld Strategic Advisors sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2020, closing a stake of 7,600 shares — an estimated $384K sold.

Schonfeld Strategic Advisors first reported a position in EIDX in Q3 2018 and held it in 6 quarters. The position peaked at $4.34M in Q1 2019. 121 funds tracked by Wall St. Rank hold EIDX as of Q4 2020.

Schonfeld Strategic Advisors reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Schonfeld Strategic Advisors sold 7,600 Eidos Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $384K.
Schonfeld Strategic Advisors first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 6 quarters.
Schonfeld Strategic Advisors's Eidos Therapeutics, Inc. Common Stock position peaked at $4.34M in Q1 2019.
121 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.